TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00710424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT03595345

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT01169844

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other
Study: NCT03595345

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT01290367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Single injection of saline solution
Description: Intradiscal control injection with saline solution

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single injection of hyaluronic acid
Description: Intradiscal control injection with hyaluronic acid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
Study: NCT02719782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: TCR-T
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study: NCT03701750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (enoxaparin sodium)
Description: enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
Study: NCT00178490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High blood pressure treatment
Description: Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
Study: NCT04638790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 i.v. day 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 i.v. day 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10,000 units/m2 i.v. days 1,15 for ABVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m2 i.v. days 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m2 i.v. days 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. days 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. days 1,15 for ABVD/AVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 i.v. days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 i.v. days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 i.v. day 1 for EACODD-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 i.v. day 1 for EACODD-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 650 mg/m2 i.v. day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 650 mg/m2 i.v. day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 i.v. day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 i.v. day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg i.v. days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg i.v. days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. day 1 for EACODD-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. day 1 for EACODD-14
Study: NCT04539158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Current Cardioversion
Description: The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Current Cardioversion
Description: The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
Study: NCT03923114

Intervention type: RADIATION
Group type: OTHER
Intervention: Ga-68-NODAGA-exendin-4 PET/CT
Description: PET/CT imaging after injection with Ga-68-NODAGA-exendin-4

Intervention type: RADIATION
Group type: OTHER
Intervention: Ga-68-NODAGA-exendin-4 PET/CT
Description: PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
Study: NCT02239692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PICOPREP
Description: Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PICOPREP
Description: Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
Study: NCT02176642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin extended release
Description: 5mg tablet taken by mouth daily for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation
Description: In office therapy administered for 30 minutes once every week for a total of 6 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation
Description: In office therapy administered for 30 minutes once every week for a total of 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet taken by mouth daily for 6 weeks
Study: NCT04196270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
Study: NCT01783899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care
Study: NCT03128073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carry life system, ultrafiltration (CLS UF)
Description: The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
Study: NCT02574260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Administered by intratumoral injection.
Study: NCT02609178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FGP
Description: To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVR
Description: the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
Study: NCT01598415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT03749525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shenfu injection
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: shenfu injection
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
Study: NCT03644459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYN00101
Description: Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg.
Study: NCT01185639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
Study: NCT01364259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine and CyberKnife stereotactic radiosurgery
Study: NCT00376259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir dipivoxil
Description: 10 mg of adefovir by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: 10 mg of adefovir by mouth once daily
Study: NCT03660930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib hydrochloride
Description: Given PO
Study: NCT01364259

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CyberKnife stereotactic radiosurgery
Description: CyberKnife stereotactic radiosurgery
Study: NCT02540720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01699672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group information
Description: The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
Study: NCT03653962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video assisted group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-video group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-video group
Study: NCT03517176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be provided as solution to be administered via IV infusion.
Study: NCT02858804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2, IV d1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m2, IV, d1-4
Study: NCT02540720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma globulin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Study: NCT02858804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 30 mg/d, d1-5
Study: NCT03957317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye mask and ear plugs
Description: Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
Study: NCT02858804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m2, IV, d1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 ,d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2, q12h, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/ m2,IV, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-150mg/d, po, d1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5mg/Kg, po, qod
Study: NCT01780012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention program
Description: Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
Study: NCT05682209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Injection
Description: 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
Study: NCT00386100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 6 mg/1500 mg (ttd)
Description: One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
Study: NCT04574713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Oral Tablet 8 mg
Description: 1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Oral Tablet 16 mg
Description: 1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
Study: NCT01616836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous FNB
Description: femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single femoral nerve block
Description: single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration analgesia
Description: placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
Study: NCT00386100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 4 mg/1000 mg (ttd)
Description: One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 2 mg/500 mg (ttd)
Description: one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 8 mg/ 2000 mg (ttd)
Description: Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 500 mg (ttd)
Description: One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1000 mg (ttd)
Description: One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1500 mg (ttd)
Description: One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 2000 mg (ttd)
Description: Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
Study: NCT03015909

Intervention type: DRUG
Group type: OTHER
Intervention: Somatropin
Study: NCT00656396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)
Description: Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Standard care
Study: NCT00731510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate energy drink
Description: Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Aspartame dissolved in water, ad libitum, 22 days.
Study: NCT01166997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkoSonic Endovascular System
Description: The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Intravenous unfractionated heparin used for anticoagulation treatment
Study: NCT01997099

Intervention type: DEVICE
Intervention: CADD®-Solis VIP Pump

Intervention type: DEVICE
Intervention: CADD®-Solis VIP Pump

Intervention type: DEVICE
Intervention: CADD®-Solis VIP Pump

Intervention type: DEVICE
Intervention: CADD®-Solis VIP Pump

Intervention type: DEVICE
Intervention: CADD™ Solis Medication Safety Software Administrator

Intervention type: DEVICE
Intervention: CADD™ Solis Medication Safety Software Administrator
Study: NCT00858234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
Study: NCT03156582

Intervention type: OTHER
Intervention: Data collecting
Study: NCT03333382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic biliary stent
Description: Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS
Description: FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.